- Home
- ROIV vs FIGR Comparison
ROIV vs FIGR Comparison
Compare ROIV & FIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- FIGR
- Stock Information
- Founded
- ROIV 2014
- FIGR 2018
- Country
- ROIV United Kingdom
- FIGR United States
- Employees
- ROIV N/A
- FIGR N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- FIGR Finance: Consumer Services
- Sector
- ROIV Health Care
- FIGR Finance
- Exchange
- ROIV Nasdaq
- FIGR Nasdaq
- Market Cap
- ROIV 8.6B
- FIGR 6.9B
- IPO Year
- ROIV N/A
- FIGR 2025
- Fundamental
- Price
- ROIV $14.08
- FIGR N/A
- Analyst Decision
- ROIV Strong Buy
- FIGR
- Analyst Count
- ROIV 4
- FIGR 0
- Target Price
- ROIV $15.50
- FIGR N/A
- AVG Volume (30 Days)
- ROIV 6.6M
- FIGR 25.1M
- Earning Date
- ROIV 11-11-2025
- FIGR 01-01-0001
- Dividend Yield
- ROIV N/A
- FIGR N/A
- EPS Growth
- ROIV N/A
- FIGR N/A
- EPS
- ROIV N/A
- FIGR 1.25
- Revenue
- ROIV $23,233,000.00
- FIGR $327,242,000.00
- Revenue This Year
- ROIV N/A
- FIGR N/A
- Revenue Next Year
- ROIV $281.14
- FIGR N/A
- P/E Ratio
- ROIV N/A
- FIGR $26.00
- Revenue Growth
- ROIV N/A
- FIGR 81.34
- 52 Week Low
- ROIV $8.73
- FIGR $30.01
- 52 Week High
- ROIV $14.48
- FIGR $38.05
- Technical
- Relative Strength Index (RSI)
- ROIV 76.40
- FIGR N/A
- Support Level
- ROIV $11.85
- FIGR N/A
- Resistance Level
- ROIV $14.48
- FIGR N/A
- Average True Range (ATR)
- ROIV 0.42
- FIGR 0.00
- MACD
- ROIV 0.21
- FIGR 0.00
- Stochastic Oscillator
- ROIV 86.26
- FIGR 0.00
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.